A novel approach for determining cancer genomic breakpoints in the presence of normal DNA

PLoS ONE

Volumn 2, Issue 4, 2007, Pages

  Liu, Yu Tsueng ^a   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PRIMER DNA;

ANALYTIC METHOD; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA MICROARRAY; DNA SEQUENCE; GENE DELETION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENE MAPPING; GENE REARRANGEMENT; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIMER APPROXIMATION MULTIPLEX POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VALIDATION PROCESS; CELL LINE; GENETICS; GENOMICS; MOLECULAR CLONING; NEOPLASM; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; DNA; DNA PRIMERS; GENES, P16; GENOMICS; HUMANS; NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION;

EID: 36448962062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000380     Document Type: Article

References (59)

1. Armour JA, Barton DE, Cockburn DJ, Taylor GR (2002) The detection of large deletions or duplications in genomic DNA. Hum Mutat 20: 325-337.
2. Heisterkamp N, Groffen J (2002) Philadelphia-positive leukemia: a personal perspective. Oncogene 21: 8536-8540.
3. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, et al. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
5. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, et al. (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212.
6. Rocco JW, Sidransky D (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264: 42-55.
7. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-177.
8. Sharpless NE (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576: 22-38.
9. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909.
10. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5: 311-316.
11. Maley CC, Reid BJ (2005) Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 15: 474-483.
12. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
13. Kim WY, Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
14. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
15. Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235-246.
16. Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522.
17. Gil J, Peters G (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667-677.
18. Kinzler KW, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761, 763.
19. Vogelstein B, Kinzler KW (2002) The genetic basis of human cancer. New York: McGraw-Hill Professional.
20. Vastag B (2006) NIH Institutes launch joint venture to map cancer genome. J Natl Cancer Inst 98: 162.
21. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267.
22. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, et al. (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16: 1465-1479.
23. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, et al. (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 101: 9067-9072.
24. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, et al. (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315: 642-645.
25. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, et al. (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341-345.
26. Perry A, Nobori T, Ru N, Anderl K, Borell TJ, et al. (1997) Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56: 999-1008.
27. Kees UR, Terry PA, Ford J, Everett J, Murch A, et al. (2005) Detection of hemizygous deletions in genomic DNA from leukaemia specimens for the diagnosis of patients. Leuk Res 29: 165-171.
28. Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, et al. (2001) Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 97: 572-574.
29. M'Soka TJ, Nishioka J, Taga A, Kato K, Kawasaki H, et al. (2000) Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia 14: 935-940.
30. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, et al. (1996) Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 88: 3083-3090.
31. Pinkel D, Albertson DG (2005) Array comparative genomic hybridization and its applications in cancer. Nat Genet 37 Suppl: S11-17.
32. Volik S, Zhao S, Chin K, Brebner JH, Herndon DR, et al. (2003) End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A 100: 7696-7701.
33. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, et al. (1996) Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A 93: 6203-6208.
34. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R 3rd, et al. (1995) Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A 92: 6489-6493.
35. Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, et al. (2006) Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol 24: 296- 305.
36. Jansen G, Hazendonk E, Thijssen KL, Plasterk RH (1997) Reverse genetics by chemical mutagenesis in Caenorhabditis elegans. Nat Genet 17: 119-121.
37. Sasaki S, Kitagawa Y, Sekido Y, Minna JD, Kuwano H, et al. (2003) Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 22: 3792-3798.
38. Raschke S, Balz V, Efferth T, Schulz WA, Florl AR (2005) Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer 42: 58-67.
39. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32.
40. Fan JB, Chee MS, Gunderson KL (2006) Highly parallel genomic assays. Nat Rev Genet 7: 632-644.
41. Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, et al. (2005) Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309: 1728-1732.
42. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376-380.
43. Service RF (2006) Gene sequencing. The race for the $1000 genome. Science 311: 1544-1546.
44. Wang HY, Luo M, Tereshchenko IV, Frikker DM, Cui X, et al. (2005) A genotyping system capable of simultaneously analyzing>1000 single nucleotide polymorphisms in a haploid genome. Genome Res 15: 276-283.
45. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, et al. (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470.
46. To EW, Chan KC, Leung SF, Chan LY, To KF, et al. (2003) Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9: 3254-3259.
47. Cayuela JM, Gardie B, Sigaux F (1997) Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 90: 3720-3726.
48. Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, et al. (2002) Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem 277: 46289-46297.
49. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, et al. (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17: 1013-1034.
50. Goulden N, Virgo P, Grimwade D (2006) Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. Br J Haematol 134: 273-282.
51. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37.
52. Szczepanski T (2007) Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia..
53. Cazzaniga G, Gaipa G, Rossi V, Biondi A (2006) Monitoring of minimal residual disease in leukemia, advantages and pitfalls. Ann Med 38: 512-521.
54. Janz S (2006) Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst) 5: 1213-1224.
55. Joos S, Falk MH, Lichter P, Haluska FG, Henglein B, et al. (1992) Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet 1: 625-632.
56. Joos S, Haluska FG, Falk MH, Henglein B, Hameister H, et al. (1992) Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc. Cancer Res 52: 6547-6552.
57. Eisen MB, Brown PO (1999) DNA arrays for analysis of gene expression. Methods Enzymol 303: 179-205.
58. Wang D, Urisman A, Liu YT, Springer M, Ksiazek TG, et al. (2003) Viral discovery and sequence recovery using DNA microarrays. PLoS Biol 1: E2.
59. Hubbard T, Andrews D, Caccamo M, Cameron G, Chen Y, et al. (2005) Ensembl 2005. Nucleic Acids Res 33: D447-453.